The trigeminal neuralgia treatment market is anticipated to rise due to the growing geriatric population because older people are more likely to get the condition. The majority of those who suffer from trigeminal neuralgia are over 50. Any age, even infancy, can experience it. TN is most likely to occur in young individuals with multiple sclerosis. 12 new instances per 100,000 people are reported annually, according to the National Institute of Neurological Disorders and Stroke (NINDS). Women experience the disease more frequently than do men. In young people, the aetiology is typically idiopathic, but compared to elderly people, adult cases are typically brought on by injury to the central nervous system, much like people with multiple sclerosis. Medication and surgery make up the two main categories of the trigeminal neuralgia market. If medication fails to relieve the symptoms of trigeminal neuralgia or has bothersome side effects, surgery is performed. Rhizotomy, stereotactic radiosurgery, and microvascular decompression are the three basic surgical procedures. Under general anaesthesia, rhizotomy is a procedure that is done outside of the hospital.
According to Coherent Market Insights, The market for Trigeminal Neuralgia (TN) Treatment was worth USD 169.30 million in 2019 and is anticipated to increase at a CAGR of 5.1% from 2020 to 2029.
Leading Companies in the Trigeminal Neuralgia Treatment Industry:
1. Pfizer Inc.
The business is headquartered in Manhattan in New York City and was founded in 1849. Pfizer's medical research and medicine and vaccine development serve the fields of immunology, cancer, the heart, endocrinology, and neurology. The company successfully acquired Biohaven Pharma's calcitonin gene-related peptide programmes in October 2022. Pfizer bought Amplyx Pharmaceuticals and the antifungal drug fosmanogepix in April 2021. (APX001).
2. Novartis
The company was founded in March 1996 and has its main offices in Basel, Switzerland, and Cambridge, Massachusetts, in the United States. Novartis provides coverage for all types of medications, including authorization, over-the-counter, immunisations, diagnostics, eyewear, and veterinary care. Through its firms, Novartis engages in a number of direct activities, including managing, advertising, operations, and research.
3. GlaxoSmithKline Plc
The company was established in 2000 and is based in Brentford, United Kingdom. The business creates, produces, and sells consumer health goods as well as prescription and over-the-counter medications, vaccinations, and other medications. GSK announced in April 2023 that it would pay $2.0 billion to purchase BELLUS Health Inc. The company announced in April 2022 that it will purchase Sierra Oncology Inc for $1.9 billion, or $55 per share. GSK purchased a 10% investment in the German biotech firm CureVac in July 2020.
4. Biogen, Inc.
The business was founded in 1978 and has its US headquarters in Cambridge, Massachusetts. The company specialises in the research, creation, and global distribution of pharmaceuticals for the treatment of neurological diseases. In February 2020, Biogen and Sangamo Therapeutics established a global licencing deal to develop medications for neurological and neuromuscular disorders.
5. Abbott Laboratories
The business was founded in 1888, and Chicago, Illinois serves as its US headquarters. It offers healthy goods, brand-name generic medications, medical supplies, and diagnostics. Abbott unveiled its Lingo line of consumer biowearable sensors in January 2022. Lingo gathers a variety of biological measurements to optimise diet and exercise plans. In August 2022, the FDA approved Abbott's Proclaim Plus, a multipurpose spinal cord stimulation device for treating chronic pain.
6. Allergan Plc
The company was founded in 2013 and is based in Dublin, Ireland. The company buys, develops, produces, and markets name-brand medications and medical equipment in the fields of gastroenterology, eye care, central nervous system, and medical aesthetics. AbbVie finalised the acquisition of Allergan on May 8, 2020.
7. Trigemina Inc.
The firm was started in 2006 and has its main office in California, United States. The company Trigemina, Inc. is a pharmaceutical enterprise. The company conducts research on pathways that target the central nervous system to create medicines for both acute and chronic pain. In June 2020, Tonix Pharmaceuticals announced the acquisition of Trigemina's non-addictive migraine and pain treatment programmes and the assumption of the licence.
Definition: Trigeminal neuralgia (TN), often called tic douloureux, is a chronic pain condition that affects the trigeminal nerve, which is located on the fifth cranial nerve. Due to systemic illnesses including Lyme disease, sarcoidosis, and multiple sclerosis, it leads to inflammatory disorders.
